Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 21,191 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Terminated No phase listed Observational

STAT3 in T Cells: At The Crossroads of Inflammation and Cancer

NCT01663571
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 19, 2026, 4:59 PM EDT
Terminated Phase 1 Interventional

FT516 in Subjects With Advanced Hematologic Malignancies

NCT04023071
View directory record Official record
Conditions
Acute Myelogenous Leukemia, B-cell Lymphoma
Interventions
FT516, Rituximab, Obinutuzumab, Cyclophosphamide, Fludarabine, IL-2, Bendamustine
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • San Diego, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 19, 2026, 4:59 PM EDT
Active, not recruiting Phase 4 Interventional

Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

NCT06049134
View directory record Official record
Conditions
Lymphoma
Interventions
PCV20
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 19, 2026, 4:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oral Metagenomic Biomarkers in Rheumatoid Arthritis

NCT02544334
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Dental Plaque, Multi-dimensional health assessment questionnaire (MDHAQ), Saliva Collection
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 19, 2026, 4:59 PM EDT
Withdrawn Phase 2 Interventional

Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL

NCT04448834
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
Blinatumomab
Drug
Lead sponsor
Dorothy Sipkins, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Tampa, Florida • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 19, 2026, 4:59 PM EDT
Completed No phase listed Observational

Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study

NCT00341198
View directory record Official record
Conditions
Autoimmune Disease
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
Not listed
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Iowa City, Iowa • Durham, North Carolina • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 4:59 PM EDT
Completed Not applicable Interventional Results available

Improving Prospective Memory Via Telehealth

NCT05129293
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Prospective Memory Intervention, Educational
Behavioral
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 19, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

NCT02458014
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Philadelphia Chromosome Positive
Interventions
Blinatumomab, TKI
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy

NCT02612155
View directory record Official record
Conditions
Moderate or Severe Hypoxic-ischemic Encephalopathy in Newborns
Interventions
Infusion of autologous cord blood, Placebo
Biological
Lead sponsor
Michael Cotten
Other
Eligibility
0 Hours to 6 Hours
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 19, 2026, 4:59 PM EDT
Completed Not applicable Interventional

Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas

NCT00152126
View directory record Official record
Conditions
Neuroblastoma, Central Nervous System Tumors, Lymphomas, Wilms Tumor
Interventions
Stem Cell Transplantation, Busulfan, Melphalan
Procedure · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 25 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 13, 2009 · Synced Oct 19, 2026, 4:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT02728050
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Cladribine, Cytarabine, Filgrastim, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Mitoxantrone, Sorafenib
Drug · Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 19, 2026, 4:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

NCT06249191
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography, Etoposide, Magnetic Resonance Imaging, Mosunetuzumab, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Vincristine
Procedure · Drug · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 19, 2026, 4:59 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Pilot Study of Nocturnal Hypoglycemia Prevention in Type 1 Diabetes Using the Vigilant Diabetes Management Companion

NCT02906891
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
Vigilant Diabetes Management Application
Device
Lead sponsor
InSpark Technologies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 19, 2026, 4:59 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

NCT05108818
View directory record Official record
Conditions
Influenza, Human
Interventions
Seasonal influenza vaccine
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 19, 2026, 4:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

NCT00068718
View directory record Official record
Conditions
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma
Interventions
Therapeutic Allogeneic Lymphocytes
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 19, 2026, 4:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Trans Women Connected Mobile App for Changes in Sexual Health-related Behavior Among Transgender Women

NCT03897049
View directory record Official record
Conditions
HIV/AIDS, Health Knowledge, Attitudes, Practice, STI
Interventions
Trans Women Connected, General Health App
Behavioral
Lead sponsor
ETR Associates
Other
Eligibility
18 Years to 49 Years
Enrollment
574 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Scotts Valley, California
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 19, 2026, 4:59 PM EDT
Completed Not applicable Interventional

Advancing Diabetes Management in Adolescents Using Health Information Technology

NCT02115555
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
HIT-aided approach, Contracted conflict management system, HIT plus contracted conflict management
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 18 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 19, 2026, 4:59 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity

NCT02499978
View directory record Official record
Conditions
HIV/AIDS
Interventions
Darunavir/Cobicistat, Dolutegravir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 19, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional Results available

Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT00262925
View directory record Official record
Conditions
Recurrent Adult Acute Lymphoblastic Leukemia
Interventions
alemtuzumab, asparaginase, methotrexate, dexamethasone, leucovorin calcium, mercaptopurine, vincristine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
58
States / cities
Aurora, Illinois • Chicago, Illinois • Joliet, Illinois + 43 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 19, 2026, 4:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

NCT02243189
View directory record Official record
Conditions
Healthy, Asthma
Interventions
JNJ-43260295, Placebo, Nasal Allergen Challenge
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 19, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional Results available

Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

NCT01010568
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ofatumumab and Bendamustine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 19, 2026, 4:59 PM EDT
Recruiting Phase 1 Interventional

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

NCT06420089
View directory record Official record
Conditions
T Cell Non-Hodgkin Lymphoma
Interventions
Senza5 CART5
Drug
Lead sponsor
Vittoria Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 19, 2026, 4:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

NCT02867618
View directory record Official record
Conditions
Hodgkin Disease, Lymphoma, Non-hodgkin
Interventions
Carfilzomib, TGR-1202
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 19, 2026, 4:59 PM EDT
Completed Not applicable Interventional

CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation

NCT00333190
View directory record Official record
Conditions
Hematologic Malignancy, AML, ALL, CML, Multiple Myeloma, NHL, Hodgkin's Lymphoma
Interventions
CD+8 T cell depletion
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 19, 2026, 4:59 PM EDT